{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:08:28Z","timestamp":1792602508290,"version":"4.5.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T00:00:00Z","timestamp":1700438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T00:00:00Z","timestamp":1700438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008977","name":"Universit\u00e4t Ulm","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008977","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Transjugular intrahepatic portosystemic shunt (TIPS) is a well-validated treatment option for clinically significant portal hypertension (CSPH) in the context of liver cirrhosis. Its high efficacy and safety in the management of treatment-refractory ascites and variceal bleeding have been extensively proven. Contraindications for TIPS include severe right heart failure, hepatic encephalopathy, and sepsis. However, the role of liver malignancy in TIPS is debatable. Mostly, primary liver malignancies such as hepatocellular carcinoma (HCC) emerge from advanced liver diseases. Coexisting portal hypertension in HCC often results in limited treatment options and a poor prognosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Summary<\/jats:title>\n                <jats:p>Previous studies have shown that TIPS implantation in patients with HCC is technically feasible and is usually not associated with major adverse events. Furthermore, TIPS may help in bridging the time to liver transplantation in early HCC and allow for locoregional treatment in advanced HCC. However, several studies suggest that seeding tumour cells to the lungs by TIPS placement might worsen the prognosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>TIPS placement in patients with coexisting liver malignancy remains a case-by-case decision, and there is no profound evidence allowing general recommendations. This review aims to provide a state-of-the-art overview of the potential risks and benefits of TIPS placement in patients with liver malignancies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-023-03047-0","type":"journal-article","created":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T14:02:41Z","timestamp":1700488961000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Risks and benefits of TIPS in HCC and other liver malignancies: a literature review"],"prefix":"10.1186","volume":"23","author":[{"given":"Anna","family":"Fichtl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Seufferlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugen","family":"Zizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,20]]},"reference":[{"key":"3047_CR1","doi-asserted-by":"crossref","unstructured":"Sauerbruch T, Schierwagen R, Trebicka J. Managing portal Hypertension in patients with liver Cirrhosis [version 1; referees: 2 approved]. F1000Research. 2018;7.","DOI":"10.12688\/f1000research.13943.1"},{"key":"3047_CR2","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","volume":"76","author":"R de Franchis","year":"2022","unstructured":"de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Abraldes JG, et al. Baveno VII \u2013 renewing consensus in portal Hypertension. J Hepatol. 2022;76:959\u201374.","journal-title":"J Hepatol"},{"issue":"2","key":"3047_CR3","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1177\/2050640620952637","volume":"9","author":"A Horhat","year":"2021","unstructured":"Horhat A, Bureau C, Thabut D, Rudler M. Transjugular intrahepatic portosystemic shunt in patients with Cirrhosis: indications and posttransjugular intrahepatic portosystemic shunt Complications in 2020. United Eur Gastroenterol J. 2021;9(2):203\u20138.","journal-title":"United Eur Gastroenterol J"},{"issue":"7","key":"3047_CR4","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/ueg2.12286","volume":"10","author":"S Sidali","year":"2022","unstructured":"Sidali S, Tr\u00e9po E, Sutter O, Nault JC. New concepts in the treatment of hepatocellular carcinoma. United Eur Gastroenterol J. 2022;10(7):765\u201374.","journal-title":"United Eur Gastroenterol J"},{"key":"3047_CR5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Reviews Disease Primers. 2021;7:6.","journal-title":"Nat Reviews Disease Primers"},{"issue":"8","key":"3047_CR6","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1016\/j.clinre.2021.101790","volume":"46","author":"E Larrey","year":"2022","unstructured":"Larrey E, Cluzel P, Rudler M, Goumard C, Damais-Thabut D, Allaire M. TIPS for patients with early HCC: a bridge to liver transplantation. Clin Res Hepatol Gastroenterol. 2022;46(8):e6.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"3047_CR7","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0168-8278(96)80065-1","volume":"25","author":"D Lebrec","year":"1996","unstructured":"Lebrec D, Giuily N, Hadengue A, Vilgrain V, Moreau R, Poynard T, et al. Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with Cirrhosis and refractory Ascites: a randomized trial. J Hepatol. 1996;25:135\u201344.","journal-title":"J Hepatol"},{"issue":"6","key":"3047_CR8","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1053\/gast.2002.37073","volume":"123","author":"P Gin\u00e8s","year":"2002","unstructured":"Gin\u00e8s P, Uriz J, Calahorra B, Garcia-Tsao G, Kamath PS, del Arbol LR, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory Ascites in Cirrhosis. Gastroenterology. 2002;123(6):1839\u201347.","journal-title":"Gastroenterology"},{"issue":"3","key":"3047_CR9","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1002\/hep.20364","volume":"40","author":"F Salerno","year":"2004","unstructured":"Salerno F, Merli M, Riggio O, Cazzaniga M, Valeriano V, Pozzi M, et al. Randomized controlled study of TIPS versus paracentesis plus albumin in Cirrhosis with severe Ascites. Hepatology. 2004;40(3):629\u201335.","journal-title":"Hepatology"},{"issue":"7","key":"3047_CR10","first-page":"858","volume":"18","author":"Y Narahara","year":"2007","unstructured":"Narahara Y, Kanazawa H, Fukuda T, Matsushita Y, Harimoto H, Kidokoro H, et al. Transjugular intrahepatic portosystemic shunt using covered stents for refractory Ascites: midterm results. J Vasc Interv Radiol. 2007;18(7):858\u201365.","journal-title":"J Vasc Interv Radiol"},{"issue":"1","key":"3047_CR11","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1053\/j.gastro.2016.09.016","volume":"152","author":"C Bureau","year":"2017","unstructured":"Bureau C, Thabut D, Oberti F, Dharancy S, Carbonell N, Bouvier A, et al. Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with Cirrhosis and recurrent Ascites. Gastroenterology. 2017;152(1):157\u201363e7.","journal-title":"Gastroenterology"},{"issue":"3","key":"3047_CR12","doi-asserted-by":"publisher","first-page":"784","DOI":"10.4103\/jcrt.jcrt_467_21","volume":"17","author":"H Dong","year":"2021","unstructured":"Dong H, Zhang C, Li Z, Yang H, Wang Y, Liu J, et al. Trans-jugular intrahepatic portosystemic shunt in patients with hepatic cellular carcinoma: a preliminary study. J Cancer Res Ther. 2021;17(3):784\u20139.","journal-title":"J Cancer Res Ther"},{"issue":"6","key":"3047_CR13","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1111\/hepr.12162","volume":"44","author":"L Liu","year":"2014","unstructured":"Liu L, Zhao Y, Qi X, Cai G, He C, Guo W, et al. Transjugular intrahepatic portosystemic shunt for symptomatic portal Hypertension in hepatocellular carcinoma with portal vein Tumor Thrombosis. Hepatol Res. 2014;44(6):621\u201330.","journal-title":"Hepatol Res"},{"issue":"1","key":"3047_CR14","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/apt.12994","volume":"41","author":"D Bettinger","year":"2015","unstructured":"Bettinger D, Kn\u00fcppel E, Euringer W, Spangenberg HC, R\u00f6ssle M, Thimme R, et al. Efficacy and safety of transjugular intrahepatic portosystemic shunt (TIPSS) in 40 patients with hepatocellular carcinoma. Aliment Pharmacol Ther. 2015;41(1):126\u201336.","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"3047_CR15","doi-asserted-by":"publisher","first-page":"6777","DOI":"10.1007\/s00330-022-08705-7","volume":"32","author":"Z Qiu","year":"2022","unstructured":"Qiu Z, Wang G, Yan H, Qi H, Zuo M, Wang G, et al. TIPS plus sequential systemic therapy of advanced HCC patients with tumour thrombus-related symptomatic portal Hypertension. Eur Radiol. 2022;32(10):6777\u201387.","journal-title":"Eur Radiol"},{"issue":"13","key":"3047_CR16","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.12998\/wjcc.v7.i13.1599","volume":"7","author":"SH Luo","year":"2019","unstructured":"Luo SH, Chu JG, Huang H, Yao KC. Safety and efficacy of transjugular intrahepatic portosystemic shunt combined with palliative treatment in patients with hepatocellular carcinoma. World J Clin Cases. 2019;7(13):1599\u2013610.","journal-title":"World J Clin Cases"},{"issue":"7","key":"3047_CR17","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.jvir.2021.04.005","volume":"32","author":"J Tsauo","year":"2021","unstructured":"Tsauo J, Tie J, Xue H, Zhao JB, Li JJ, Fang ZT, et al. Transjugular Intrahepatic Portosystemic Shunt Creation for the Prevention of gastric variceal rebleeding in patients with Hepatocellular Carcinoma: a Multicenter Retrospective Study. J Vasc Interv Radiol. 2021;32(7):963\u20139.","journal-title":"J Vasc Interv Radiol"},{"key":"3047_CR18","doi-asserted-by":"crossref","unstructured":"Yan H, Qiu Z, Xiang Z, Feng K, Huang M, Gao F. TIPS improves outcomes in patients with HCC and symptomatic portal Hypertension: a multi-institution experience. Cancer Imaging. 2022;22(1).","DOI":"10.1186\/s40644-022-00451-9"},{"key":"3047_CR19","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1056\/NEJMoa0910102","volume":"362","author":"JC Garc\u00eda-Pag\u00e1n","year":"2010","unstructured":"Garc\u00eda-Pag\u00e1n JC, Caca K, Bureau C, Laleman W, Luca A, Abraldes JG, et al. Early Use of TIPS in patients with Cirrhosis and variceal bleeding. N Engl J Med. 2010;362:2370\u20139.","journal-title":"N Engl J Med"},{"issue":"8","key":"3047_CR20","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/S2468-1253(19)30090-1","volume":"4","author":"Y Lv","year":"2019","unstructured":"Lv Y, Yang Z, Liu L, Li K, He C, Wang Z, et al. Early TIPS with covered stents versus standard treatment for acute variceal bleeding in patients with advanced Cirrhosis: a randomised controlled trial. Lancet Gastroenterol Hepatol. 2019;4(8):587\u201398.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"3047_CR21","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/hep.30182","volume":"69","author":"V Hern\u00e1ndez-Gea","year":"2019","unstructured":"Hern\u00e1ndez-Gea V, Procopet B, Gir\u00e1ldez \u00c1, Amitrano L, Villanueva C, Thabut D, et al. Preemptive-TIPS improves outcome in high-risk variceal bleeding: an observational study. Hepatology. 2019;69(1):282\u201393.","journal-title":"Hepatology"},{"issue":"7","key":"3047_CR22","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1136\/gutjnl-2018-317057","volume":"68","author":"Y Lv","year":"2019","unstructured":"Lv Y, Zuo L, Zhu X, Zhao J, Xue H, Jiang Z, et al. Identifying optimal candidates for early TIPS among patients with Cirrhosis and acute variceal bleeding: a multicentre observational study. Gut. 2019;68(7):1297\u2013310.","journal-title":"Gut"},{"key":"3047_CR23","doi-asserted-by":"crossref","unstructured":"Lv Y, Bai W, Zhu X, Xue H, Zhao J, Zhuge Y et al. CLIF-C AD score predicts survival benefit from pre-emptive TIPS in individuals with child-pugh B Cirrhosis and acute variceal bleeding. JHEP Rep. 2022;100621.","DOI":"10.1016\/j.jhepr.2022.100621"},{"issue":"11","key":"3047_CR24","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1111\/j.1572-0241.2004.40336.x","volume":"99","author":"BH Lang","year":"2004","unstructured":"Lang BH, Poon RT, Fan ST, Wong J. Outcomes of patients with hepatocellular carcinoma presenting with variceal bleeding. Am J Gastroenterol. 2004;99(11):2158\u201365.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"3047_CR25","doi-asserted-by":"publisher","first-page":"500","DOI":"10.5009\/gnl19155","volume":"14","author":"YR Lee","year":"2020","unstructured":"Lee YR, Park SY, Tak WY. Treatment outcomes and prognostic factors of acute variceal bleeding in patients with hepatocellular carcinoma. Gut Liver. 2020;14(4):500\u20138.","journal-title":"Gut Liver"},{"issue":"9","key":"3047_CR26","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1016\/j.jvir.2020.06.005","volume":"31","author":"A Niekamp","year":"2020","unstructured":"Niekamp A, Kuban JD, Lee SR, Yevich S, Metwalli Z, McCarthy CJ, et al. Transjugular Intrahepatic Portosystemic shunts reduce Variceal bleeding and improve survival in patients with Cirrhosis: a Population-based analysis. J Vasc Interv Radiol. 2020;31(9):1382\u201391e2.","journal-title":"J Vasc Interv Radiol"},{"issue":"9","key":"3047_CR27","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1097\/MEG.0000000000001686","volume":"32","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Zhang W, Zhang Z, Luo J, Gu J, Liu Q, et al. PTFE-covered TIPS is an effective treatment for secondary preventing variceal rebleeding in cirrhotic patients with high risks. Eur J Gastroenterol Hepatol. 2020;32(9):1235\u201343.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"6","key":"3047_CR28","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1002\/hep.26629","volume":"58","author":"C Ripoll","year":"2013","unstructured":"Ripoll C, Genesc\u00e0 J, Araujo IK, Graupera I, Augustin S, Tejedor M, et al. Rebleeding prophylaxis improves outcomes in patients with hepatocellular carcinoma. A multicenter case-control study. Hepatology. 2013;58(6):2079\u201388.","journal-title":"Hepatology"},{"key":"3047_CR29","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/BF02602989","volume":"16","author":"RP Davies","year":"1993","unstructured":"Davies RP, Richard G, Sissonsj J, Mclntosh NA. CardioVascular and lnterventional Transjugular Intrahepatic Portocaval Shunt (TIPS) and hepatic vein-to-Caval Stenting as Salvage Treatment of Portal Hypertension Secondary to Neoplasm. Cardiovasc Intervent Radiol. 1993;16:105\u20138.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"1","key":"3047_CR30","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1023\/A:1018876803292","volume":"42","author":"FM Serafini","year":"1997","unstructured":"Serafini FM, Zwiebel B, Black TJ, Carey LC, Rosemurgy AS. Transjugular Intrahepatic Portosystemic Stent Shunt in the treatment of Variceal Bleeding in Hepatocellular Cancer. Dig Dis Sci. 1997;42(1):59\u201365.","journal-title":"Dig Dis Sci"},{"issue":"6","key":"3047_CR31","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1007\/s12072-022-10388-7","volume":"16","author":"Y Chen","year":"2022","unstructured":"Chen Y, Ma X, Zhang X, Luo J, An L, Zhang Y, et al. Prevention of variceal rebleeding in cirrhotic patients with advanced hepatocellular carcinoma receiving molecularly targeted therapy: a randomized pilot study of transjugular intrahepatic portosystemic shunt versus endoscopic plus \u03b2-blocker. Hepatol Int. 2022;16(6):1379\u201389.","journal-title":"Hepatol Int"},{"issue":"5","key":"3047_CR32","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.diii.2018.10.006","volume":"100","author":"S Young","year":"2019","unstructured":"Young S, Bermudez J, Zhang L, Rostambeigi N, Golzarian J. Transjugular intrahepatic portosystemic shunt (TIPS) placement: a comparison of outcomes between patients with hepatic hydrothorax and patients with refractory Ascites. Diagn Interv Imaging. 2019;100(5):303\u20138.","journal-title":"Diagn Interv Imaging"},{"issue":"3","key":"3047_CR33","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/ajg.2009.634","volume":"105","author":"R Dhanasekaran","year":"2010","unstructured":"Dhanasekaran R, West JK, Gonzales PC, Subramanian R, Parekh S, Spivey JR, et al. Transjugular intrahepatic portosystemic shunt for symptomatic refractory hepatic hydrothorax in patients with Cirrhosis. Am J Gastroenterol. 2010;105(3):635\u201341.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"3047_CR34","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12885-020-07708-1","volume":"21","author":"J Lim","year":"2021","unstructured":"Lim J, Kim Hil, Kim E, Kim J, An J, Chang S, et al. Variceal bleeding is aggravated by portal venous invasion of hepatocellular carcinoma: a matched nested case-control study. BMC Cancer. 2021;21(1):11.","journal-title":"BMC Cancer"},{"issue":"6","key":"3047_CR35","doi-asserted-by":"publisher","first-page":"567","DOI":"10.4240\/wjgs.v14.i6.567","volume":"14","author":"XH Yan","year":"2022","unstructured":"Yan XH, Yue ZD, Zhao HW, Wang L, Fan ZH, Wu YF, et al. Transjugular intrahepatic portosystemic shunt with radioactive seed strand for main portal vein Tumor Thrombosis with cirrhotic portal Hypertension. World J Gastrointest Surg. 2022;14(6):567\u201379.","journal-title":"World J Gastrointest Surg"},{"issue":"6","key":"3047_CR36","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.3748\/wjg.v20.i6.1602","volume":"20","author":"JB Zhao","year":"2014","unstructured":"Zhao JB, Feng C, Zhu QH, He XF, Li YH, Chen Y. Transjugular intrahepatic portosystemic shunt with covered stents for hepatocellular carcinoma with portal vein Tumor Thrombosis. World J Gastroenterol. 2014;20(6):1602\u20137.","journal-title":"World J Gastroenterol"},{"issue":"13","key":"3047_CR37","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.3748\/wjg.v10.i13.1881","volume":"10","author":"ZB Jiang","year":"2004","unstructured":"Jiang ZB, Shan H, Shen XY, Huang MS, Li ZR, Zhu, Kang-Shun, et al. Transjugular intrahepatic portosystemic shunt for palliative treatment of portal Hypertension secondary to portal vein Tumor Thrombosis. World J Gastroenterol. 2004;10(13):1881\u20134.","journal-title":"World J Gastroenterol"},{"issue":"9","key":"3047_CR38","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1007\/s00270-017-1655-8","volume":"40","author":"B Qiu","year":"2017","unstructured":"Qiu B, Li K, Dong X, Liu FQ. Transjugular Intrahepatic Portosystemic Shunt for Portal Hypertension in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Cardiovasc Intervent Radiol. 2017;40(9):1372\u201382.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"3","key":"3047_CR39","doi-asserted-by":"publisher","first-page":"167","DOI":"10.18528\/gii180026","volume":"7","author":"H Zhao","year":"2018","unstructured":"Zhao H, Tsauo J, Zhang X, Gong T, Li J, Li X. Transjugular intrahepatic portosystemic shunt creation for portal Hypertension in patients with hepatocellular carcinoma: a systematic review. Int J Gastrointest Interv. 2018;7(3):167\u201371.","journal-title":"Int J Gastrointest Interv"},{"key":"3047_CR40","doi-asserted-by":"crossref","unstructured":"Yan J, Li T, Deng M, Fan H. Ruptured Hepatocellular Carcinoma: what do interventional radiologists need to know? Front Oncol. 2022;12.","DOI":"10.3389\/fonc.2022.927123"},{"key":"3047_CR41","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.trre.2018.10.004","volume":"33","author":"CM Sellers","year":"2019","unstructured":"Sellers CM, Nezami N, Schilsky ML, Kim HS. Transjugular intrahepatic portosystemic shunt as a bridge to liver transplant: current state and future directions. Transpl Rev (Orlando). 2019;33:64\u201371.","journal-title":"Transpl Rev (Orlando)"},{"issue":"3","key":"3047_CR42","doi-asserted-by":"publisher","first-page":"301","DOI":"10.15403\/jgld.2014.1121.243.yao","volume":"24","author":"J Yao","year":"2015","unstructured":"Yao J, Zuo L, An G, Yue Z, Zhao H, Wang L, et al. Risk factors for hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma and portal Hypertension. J Gastrointest Liver Dis. 2015;24(3):301\u20137.","journal-title":"J Gastrointest Liver Dis"},{"issue":"4","key":"3047_CR43","doi-asserted-by":"publisher","first-page":"100122","DOI":"10.1016\/j.jhepr.2020.100122","volume":"2","author":"JC Garc\u00eda-Pag\u00e1n","year":"2020","unstructured":"Garc\u00eda-Pag\u00e1n JC, Saffo S, Mandorfer M, Garcia-Tsao G. Where does TIPS fit in the management of patients with Cirrhosis? JHEP Rep. 2020;2(4):100122.","journal-title":"JHEP Rep"},{"issue":"5","key":"3047_CR44","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1007\/s11011-022-01131-0","volume":"38","author":"S Nardelli","year":"2023","unstructured":"Nardelli S, Bellafante D, Ridola L, Faccioli J, Riggio O, Gioia S. Prevention of post-TIPS hepatic encephalopathy: the search of the ideal candidate. Metab Brain Dis. 2023;38(5):1729\u201336.","journal-title":"Metab Brain Dis"},{"issue":"7","key":"3047_CR45","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1136\/gutjnl-2019-320221","volume":"69","author":"D Tripathi","year":"2020","unstructured":"Tripathi D, Stanley AJ, Hayes PC, Travis S, Armstrong MJ, Tsochatzis EA, et al. Transjugular intrahepatic portosystemic stent-shunt in the management of portal Hypertension. Gut. 2020;69(7):1173\u201392.","journal-title":"Gut"},{"issue":"6","key":"3047_CR46","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cgh.2016.10.028","volume":"15","author":"S Nardelli","year":"2017","unstructured":"Nardelli S, Lattanzi B, Torrisi S, Greco F, Farcomeni A, Gioia S, et al. Sarcopenia is risk factor for development of hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt Placement. Clin Gastroenterol Hepatol. 2017;15(6):934\u20136.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3047_CR47","doi-asserted-by":"publisher","first-page":"978110","DOI":"10.3389\/fnut.2022.978110","volume":"9","author":"C Jiang","year":"2022","unstructured":"Jiang C, Wang Y, Fu W, Zhang G, Feng X, Wang X, et al. Association between Sarcopenia and prognosis of hepatocellular carcinoma: a systematic review and meta-analysis. Front Nutr. 2022;9:978110.","journal-title":"Front Nutr"},{"key":"3047_CR48","doi-asserted-by":"publisher","first-page":"e934436","DOI":"10.12659\/MSM.934436","volume":"27","author":"X Zou","year":"2021","unstructured":"Zou X, Xue M, Li J. Combined use of transjugular intrahepatic portosystemic shunt and transarterial chemoembolization in the treatment of esophageal and gastric variceal bleeding: a retrospective study of 80 patients with hepatocellular carcinoma and portal Hypertension. Med Sci Monit. 2021;27:e934436.","journal-title":"Med Sci Monit"},{"issue":"47","key":"3047_CR49","doi-asserted-by":"publisher","first-page":"e23191","DOI":"10.1097\/MD.0000000000023191","volume":"99","author":"L Chang","year":"2020","unstructured":"Chang L, Wang W, Jiang N, Rao F, Gong C, Wu P, et al. Dexamethasone prevents TACE-induced adverse events: a meta-analysis. Medicine. 2020;99(47):e23191.","journal-title":"Medicine"},{"key":"3047_CR50","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3350\/cmh.2021.0239","volume":"28","author":"HL Lee","year":"2022","unstructured":"Lee HL, Lee SW. The role of transjugular intrahepatic portosystemic shunt in patients with portal Hypertension: advantages and pitfalls. Clin Mol Hepatol. 2022;28:121\u201334.","journal-title":"Clin Mol Hepatol"},{"issue":"5","key":"3047_CR51","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.2214\/AJR.20.23478","volume":"216","author":"RP Lokken","year":"2021","unstructured":"Lokken RP, Kerlan RK, Chung YC, Chen YF, Mehta NJ, Yao FY, et al. Hepatic toxicity after selective chemoembolization is associated with decreased survival among patients with hepatocellular carcinoma. AJR Am J Roentgenol. 2021;216(5):1283\u201390.","journal-title":"AJR Am J Roentgenol"},{"issue":"1","key":"3047_CR52","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jvir.2012.08.032","volume":"24","author":"MP Kohi","year":"2013","unstructured":"Kohi MP, Fidelman N, Naeger DM, Laberge JM, Gordon RL, Kerlan RK. Hepatotoxicity after transarterial chemoembolization and transjugular intrahepatic portosystemic shunt: do two rights make a wrong? J Vasc Interv Radiol. 2013;24(1):68\u201373.","journal-title":"J Vasc Interv Radiol"},{"issue":"5","key":"3047_CR53","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1007\/s00270-013-0698-8","volume":"36","author":"YC Kuo","year":"2013","unstructured":"Kuo YC, Kohi MP, Naeger DM, Tong RT, Kolli KP, Taylor AG, et al. Efficacy of TACE in TIPS patients: comparison of treatment response to chemoembolization for hepatocellular carcinoma in patients with and without a transjugular intrahepatic portosystemic shunt. Cardiovasc Intervent Radiol. 2013;36(5):1336\u201343.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"5","key":"3047_CR54","doi-asserted-by":"publisher","first-page":"671","DOI":"10.5152\/dir.2021.20358","volume":"27","author":"X Chen","year":"2021","unstructured":"Chen X, Qiu ZK, Wang GB, Chen XL, Zhang FJ, Gao F. Effect of transjugular intrahepatic portosystemic shunt on transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis. Diagn Interv Radiol. 2021;27(5):671\u20136.","journal-title":"Diagn Interv Radiol"},{"issue":"1","key":"3047_CR55","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/hep.28453","volume":"64","author":"R Lencioni","year":"2016","unstructured":"Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JFH. Lipiodol Transarterial Chemoembolization for Hepatocellular Carcinoma: a systematic review of efficacy and Safety Data. Hepatology. 2016;64(1):106\u201316.","journal-title":"Hepatology"},{"key":"3047_CR56","doi-asserted-by":"publisher","first-page":"8291","DOI":"10.1007\/s00330-021-07834-9","volume":"31","author":"W Fan","year":"2021","unstructured":"Fan W, Guo J, Zhu B, Wang S, Yu L, Huang W, et al. Drug-eluting beads TACE is safe and non-inferior to conventional TACE in HCC patients with TIPS. Eur Radiol. 2021;31:8291\u2013301.","journal-title":"Eur Radiol"},{"issue":"4","key":"3047_CR57","doi-asserted-by":"publisher","first-page":"933","DOI":"10.2214\/AJR.20.24708","volume":"217","author":"L Zhang","year":"2021","unstructured":"Zhang L, Sun JH, Ji JS, Zhong BY, Zhou GH, Song JJ, et al. Imaging changes and clinical Complications after drug-eluting bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study. AJR Am J Roentgenol. 2021;217(4):933\u201344.","journal-title":"AJR Am J Roentgenol"},{"issue":"4","key":"3047_CR58","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s00270-014-1009-8","volume":"38","author":"SA Padia","year":"2015","unstructured":"Padia SA, Chewning RH, Kogut MJ, Ingraham CR, Johnson GE, Bhattacharya R, et al. Outcomes of Locoregional Tumor Therapy for Patients with Hepatocellular Carcinoma and Transjugular Intrahepatic Portosystemic shunts. Cardiovasc Intervent Radiol. 2015;38(4):913\u201321.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"3","key":"3047_CR59","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.jhep.2022.11.019","volume":"78","author":"D Thabut","year":"2022","unstructured":"Thabut D, Kudo M. Treatment of portal Hypertension in patients with HCC at the era of Baveno VII. J Hepatol. 2022;78(3):658\u201362.","journal-title":"J Hepatol"},{"issue":"1","key":"3047_CR60","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3109\/00365528509089633","volume":"20","author":"M Bjosrneboe","year":"1985","unstructured":"Bjosrneboe M, Andersen JR, Christensen U, Skinhosj P, Jensen OM. Does a portal-systemic shunt increase the risk of primary hepatic carcinoma in Cirrhosis of the Liver? Scand J Gastroenterol. 1985;20(1):59\u201364.","journal-title":"Scand J Gastroenterol"},{"issue":"4","key":"3047_CR61","doi-asserted-by":"publisher","first-page":"826","DOI":"10.4103\/jcrt.JCRT_930_17","volume":"14","author":"J Wei","year":"2018","unstructured":"Wei J, Li H, Li C. Investigating the risk factors of hepatocellular carcinoma and survival analysis for Cirrhosis after transjugular intrahepatic portosystemic shunt in treating portal Hypertension. J Cancer Res Ther. 2018;14(4):826\u201332.","journal-title":"J Cancer Res Ther"},{"issue":"9","key":"3047_CR62","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/lt.26073","volume":"27","author":"LN Krumeich","year":"2021","unstructured":"Krumeich LN, Mancinelli J, Cucchiara A, Eddinger K, Aufhauser D, Goldberg DW, et al. Occult Hepatocellular Carcinoma Associated with Transjugular Intrahepatic Portosystemic shunts in Liver Transplant recipients. Liver Transpl. 2021;27(9):1248\u201361.","journal-title":"Liver Transpl"},{"issue":"3","key":"3047_CR63","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1177\/2050640617732886","volume":"6","author":"A H\u00fcsing-Kabar","year":"2018","unstructured":"H\u00fcsing-Kabar A, Meister T, K\u00f6hler M, Domschke W, Kabar I, Wilms C, et al. Is de novo hepatocellular carcinoma after transjugular intrahepatic portosystemic shunt increased? United Eur Gastroenterol J. 2018;6(3):413\u201321.","journal-title":"United Eur Gastroenterol J"},{"issue":"1","key":"3047_CR64","doi-asserted-by":"publisher","first-page":"20682","DOI":"10.1038\/s41598-020-77801-9","volume":"10","author":"J Chang","year":"2020","unstructured":"Chang J, Dumitrache A, B\u00f6hling N, Abu-Omar J, Meyer C, Strobel D, et al. Alteration of contrast enhanced ultrasound (CEUS) of hepatocellular carcinoma in patients with Cirrhosis and transjugular intrahepatic portosystemic shunt (TIPS). Sci Rep. 2020;10(1):20682.","journal-title":"Sci Rep"},{"key":"3047_CR65","doi-asserted-by":"crossref","unstructured":"Chen B, Pang L, Chen H bin, Wu DB, Wang YH, Chen EQ. TIPS is not associated with a higher risk of developing hcc in cirrhotic patients: A systematic review and meta-analysis. J Clin Transl Hepatol. 2019;7(3):232\u20137.","DOI":"10.14218\/JCTH.2019.00007"},{"key":"3047_CR66","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.2147\/CMAR.S192896","volume":"11","author":"C Wu","year":"2019","unstructured":"Wu C, Ren X, Zhang Q. Incidence, risk factors, and prognosis in patients with primary hepatocellular carcinoma and lung Metastasis: a population-based study. Cancer Manage Res. 2019;11:2759\u201368.","journal-title":"Cancer Manage Res"},{"issue":"4","key":"3047_CR67","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1097\/01.RVI.0000064846.87207.AB","volume":"14","author":"M Wallace","year":"2003","unstructured":"Wallace M, Swaim M. Transjugular intrahepatic portosystemic shunts through hepatic Neoplasms. J Vasc Interv Radiol. 2003;14(4):501\u20137.","journal-title":"J Vasc Interv Radiol"},{"key":"3047_CR68","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/S1072-7515(99)00026-5","volume":"188","author":"CC Wu","year":"1999","unstructured":"Wu CC, Ho WL, Chen JT, Tang CS, Yeh DC, Liu TJ. Mesohepatectomy for centrally located Hepatocellular Carcinoma: an Appraisal of a Rare Procedure. J Am Coll Surg. 1999;188:508\u201315.","journal-title":"J Am Coll Surg"},{"issue":"13","key":"3047_CR69","doi-asserted-by":"publisher","first-page":"627","DOI":"10.4254\/wjh.v9.i13.627","volume":"9","author":"WB Yu","year":"2017","unstructured":"Yu WB, Rao A, Vu V, Xu L, Rao JY, Wu JX. Management of centrally located hepatocellular carcinoma: Update 2016. World J Hepatol. 2017;9(13):627\u201334.","journal-title":"World J Hepatol"},{"issue":"2","key":"3047_CR70","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/cncr.20367","volume":"101","author":"MJ Wallace","year":"2004","unstructured":"Wallace MJ, Madoff DC, Ahrar K, Warneke CL. Transjugular intrahepatic portosystemic shunts: experience in the oncology setting. Cancer. 2004;101(2):337\u201345.","journal-title":"Cancer"},{"issue":"12","key":"3047_CR71","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/j.jvir.2018.08.007","volume":"29","author":"B Geeroms","year":"2018","unstructured":"Geeroms B, de Hertogh G, Vanslembrouck R, Wildiers H, Nevens F, Maleux G. Transjugular Intrahepatic Portosystemic Shunt for the treatment of Portal Hypertension-Induced Refractory Ascites due to metastatic Carcinomatous Liver Disease. J Vasc Interv Radiol. 2018;29(12):1713\u20136.","journal-title":"J Vasc Interv Radiol"},{"issue":"1","key":"3047_CR72","doi-asserted-by":"publisher","first-page":"279","DOI":"10.21037\/jgo-21-501","volume":"13","author":"LA Shreve","year":"2022","unstructured":"Shreve LA, O\u2019Leary C, Clark TWI, Stavropoulos SW, Soulen MC. Transjugular intrahepatic portosystemic shunt for the management of symptomatic malignant pseudocirrhosis. J Gastrointest Oncol. 2022;13(1):279\u201387.","journal-title":"J Gastrointest Oncol"},{"issue":"4","key":"3047_CR73","doi-asserted-by":"publisher","first-page":"993","DOI":"10.2214\/AJR.09.3409","volume":"194","author":"P Jha","year":"2010","unstructured":"Jha P, Poder L, Wang ZJ, Westphalen AC, Yeh BM, Coakley FV. Radiologic mimics of Cirrhosis. Am J Roentgenol. 2010;194(4):993\u20139.","journal-title":"Am J Roentgenol"},{"issue":"12","key":"3047_CR74","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.1007\/s00261-018-1592-2","volume":"43","author":"S Leshchinskiy","year":"2018","unstructured":"Leshchinskiy S, Kanner C, Keating DP, Pseudocirrhosis. Abdom Radiol (NY). 2018;43(12):3197\u20138.","journal-title":"Abdom Radiol (NY)"},{"issue":"10","key":"3047_CR75","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.3748\/wjg.14.1622","volume":"14","author":"SP Kang","year":"2008","unstructured":"Kang SP, Taddei T, McLennan B, Lacy J. Pseudocirrhosis in a Pancreatic cancer patient with liver metastases: a case report of complete resolution of pseudocirrhosis with early recognition and management. World J Gastroenterol. 2008;14(10):1622\u20134.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"3047_CR76","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3892\/mco.2021.2441","volume":"16","author":"T Shinoda","year":"2022","unstructured":"Shinoda T, Tanahashi T, Sakuratani T, Ota M, Fujibayashi S, Kiriyama S, et al. Pseudocirrhosis after chemotherapy for gastric cancer with diffuse liver metastases: a case report. Mol Clin Oncol. 2022;16(1):11.","journal-title":"Mol Clin Oncol"},{"key":"3047_CR77","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s10549-022-06771-5","volume":"197","author":"LA Huppert","year":"2023","unstructured":"Huppert LA, Walker Z, Li M, Kim MO, Callan J, Brandman D, Majure M, et al. Clinical characteristics and outcomes in patients with metastatic Breast cancer and pseudocirrhosis: a single center retrospective cohort study. Breast Cancer Res Treat. 2023;197:137\u201348.","journal-title":"Breast Cancer Res Treat"},{"issue":"43","key":"3047_CR78","doi-asserted-by":"publisher","first-page":"12439","DOI":"10.3748\/wjg.v21.i43.12439","volume":"21","author":"B Qiu","year":"2015","unstructured":"Qiu B, Zhao MF, Yue ZD, Zhao HW, Wang L, Fan ZH, et al. Combined transjugular intrahepatic portosystemic shunt and other interventions for hepatocellular carcinoma with portal Hypertension. World J Gastroenterol. 2015;21(43):12439\u201347.","journal-title":"World J Gastroenterol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-023-03047-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-023-03047-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-023-03047-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T14:19:05Z","timestamp":1700489945000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-023-03047-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,20]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3047"],"URL":"https:\/\/doi.org\/10.1186\/s12876-023-03047-0","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,20]]},"assertion":[{"value":"30 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"403"}}